Study on Erlotinib and Cabozantinib Alone or Together for Stage IV Non-small Cell Lung Cancer

Program Overview

This study is exploring how well the drugs erlotinib and cabozantinib work, either alone or in combination, as a second or third treatment option for patients with stage IV non-small cell lung cancer. These drugs may help stop cancer cells from growing by blocking certain enzymes. The study aims to find out if using both drugs together is more effective than using each one separately.

Description

The main goals of this study are to compare how long patients live without their cancer getting worse when treated with erlotinib alone, cabozantinib alone, or both drugs together. Researchers will also look at overall survival rates, how well the cancer responds to treatment, and any side effects from the treatments. Additionally, the study will investigate biological markers that might predict how well patients respond to the therapy.

Participants will be randomly assigned to one of three groups:

• Group A (Erlotinib): Patients take erlotinib by mouth every day for 28 days. This cycle repeats as long as the cancer does not progress and side effects are manageable.
• Group B (Cabozantinib): Patients take cabozantinib by mouth every day for 28 days. This cycle repeats as long as the cancer does not progress and side effects are manageable.
• Group C (Erlotinib + Cabozantinib): Patients take both erlotinib and cabozantinib as described in Groups A and B. This cycle repeats as long as the cancer does not progress and side effects are manageable.

If the cancer progresses in Groups A or B, patients may switch to the combination treatment in Group C.

After finishing the study treatment, patients will have follow-up visits every 3 months for 2 years, then every 6 months for 3 years.

Eligibility Criteria

Locations